A new report on AIDSmap states that a large number of PrEP users in the U.S. are using Descovy.
In the year following the approval of Descovy for PrEP in Oct. 2019, 29% of existing PrEP users switched to the newer formulation and 36% of new PrEP users started on it. Dr. Karen Hoover of the Centers for Disease Control and Prevention presented the data, based on a large pharmacy database, to the virtual Conference on Retroviruses and Opportunistic Infections (CROI 2021) last week.
The pharmacy data from Jan. 2014 to Sept. 2020 showed no evidence of off-label prescribing of Descovy-based PrEP before its regulatory approval, AIDSmap reported. In the last quarter of 2019, there was an immediate uptake of Descovy-based PrEP which mirrored a decline in the Truvada-based product.
People who switched to Descovy-based PrEP tended to be older and male, according to the HIV news website. Switching was also more common among Latinx individuals and people living in the south of the country. The region with the least switching was the north-east.